Galaxy Surfactants Limited filed an investor presentation under SEBI Listing Obligations and Disclosure Requirements Regulation 30(2) regarding its unaudited financial results for Q1 FY27 (quarter ended June 30, 2026).

Financial Performance Highlights

Consolidated Results:

  • Net Revenue from Operations: ₹1,781.9 Cr (39.4% YoY growth, 35.5% QoQ growth)
  • EBITDA: ₹252.5 Cr (86.9% YoY growth, 107.1% QoQ growth)
  • EBITDA Margin: 14.1% (vs 10.5% in Q1FY26 and 9.3% in Q4FY26)
  • PAT: ₹165.9 Cr (108.7% YoY growth, 165.8% QoQ growth)
  • PAT Margin: 9.3% (vs 6.2% in Q1FY26 and 4.7% in Q4FY26)
  • EPS: ₹46.80

Standalone Results:

  • Net Revenue from Operations: ₹1,265.5 Cr (44.8% YoY growth, 36.3% QoQ growth)
  • EBITDA: ₹173.8 Cr (111.3% YoY growth, 102.0% QoQ growth)
  • EBITDA Margin: 13.7% (vs 9.3% in Q1FY26 and 9.2% in Q4FY26)
  • PAT: ₹105.9 Cr (152.0% YoY growth, 140.2% QoQ growth)
  • PAT Margin: 8.3% (vs 4.8% in Q1FY26 and 4.7% in Q4FY26)
  • EPS: ₹29.88

Operational Highlights

  • Consolidated volume growth in mid-single digits with balanced contribution from Performance Surfactants and Specialty Care segments
  • EBITDA/MT improved to ₹35,458/MT
  • India business returned to double-digit volume growth after nearly two years, significantly outpacing market growth
  • AMET region witnessed low-single-digit YoY decline due to geopolitical disruptions in West Asia, but recorded high-teen sequential growth
  • ROW region delivered mid-single-digit growth led by APAC and improving momentum in Americas
  • Raw material markets remained volatile with elevated fatty alcohol prices averaging $2,806/MT in Q1FY27 (vs $2,751/MT in Q4FY26 and $2,723/MT in Q1FY26)
  • Higher petrochemical feedstock costs following increase in crude oil prices

Management Commentary

Mr. K. Natarajan, Managing Director, commented on the strategic foundations translating into tangible outcomes. He highlighted the company's ability to anticipate risks, manage volatility, make disciplined commercial decisions, and leverage a diversified portfolio. The performance was attributed to exceptional efforts across business development, commercial excellence, procurement, global logistics, manufacturing and operations. While remaining watchful of evolving geopolitical developments, the company is encouraged by recovery in customer demand, strong momentum in Specialty Care, and continued strength of India business.

Company Overview

  • 215+ Product Grades (47+ Performance Surfactants, 168+ Specialty Care Products)
  • Extensive R&D capabilities with 100+ members, R&D Centre, Pilot Plant, Product Application Centre
  • 7 strategically located facilities (5 in India, 1 in Egypt, 1 in US) with inhouse project execution capabilities
  • Serving 1,500+ clients across 95+ countries
  • 2,000+ employees across all facilities